Headquartered in Lexington, MA Fiscal year ends December NASDAQ: ALDX aldeyra.com
Aldeyra Therapeutics Inc is a pioneering biotech firm focused on creating innovative treatments for immune-mediated diseases. Its flagship product, reproxalap, aims to alleviate dry eye diseases and is currently in advanced testing stages. The company is also exploring treatments for COVID-19, asthma, psoriasis, and alcohol intoxication through ADX-629, and tackling rare retinal diseases with ADX-2191. Founded in 2004 and based in Lexington, Massachusetts, Aldeyra is committed to addressing unmet medical needs in inflammation and vision loss.
Warren Buffett boosted his stake in this tracking stock again, plus notable insider buying in the past week at biotechs, industrials and more.
A renowned billionaire investor, a French energy giant, and other insiders were scooping up shares of these five stocks as the second quarter began.
Aldeyra Therapeutics Inc is a pioneering biotech firm focused on creating innovative treatments for immune-mediated diseases. Its flagship product, reproxalap, aims to alleviate dry eye diseases and is currently in advanced testing stages.
The Wall Street consensus 12-month price target for ALDX is $6.60.
